» Articles » PMID: 30425986

Constitutive Activation of NF-κB Pathway in Hematopoietic Stem Cells Causes Loss of Quiescence and Deregulated Transcription Factor Networks

Overview
Specialty Cell Biology
Date 2018 Nov 15
PMID 30425986
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Identifying physiological roles of specific signaling pathways that regulate hematopoietic stem cell (HSC) functions may lead to new treatment strategies and therapeutic interventions for hematologic disorders. Here, we provide genetic evidence that constitutive activation of NF-κB in HSCs results in reduced pool size, repopulation capacities, and quiescence of HSCs. Global transcriptional profiling and bioinformatics studies identified loss of 'stemness' and 'quiescence' signatures in HSCs with deregulated NF-κB activation. In particular, gene set enrichment analysis identified upregulation of cyclin dependent kinase- and down regulation of cyclin dependent kinase inhibitor . Interestingly, constitutive activation of NF-κB is sufficient to alter the regulatory circuits of transcription factors (TFs) that are critical to HSC self-renewal and functions. Molecular studies identified , as one of the direct targets of NF-κB in hematopoietic cells. In essence, these studies demonstrate that aberrant activation of NF-κB signals impairs HSC quiescence and functions and alters the 'TF networks' in HSCs.

Citing Articles

Altered 3D genome reorganization mediates precocious myeloid differentiation of aged hematopoietic stem cells in inflammation.

Cui X, Dong Y, Zhan Q, Huang Y, Zhu Q, Zhang Z Sci China Life Sci. 2025; .

PMID: 39754007 DOI: 10.1007/s11427-024-2754-9.


Exploring the contribution of Zfp521/ZNF521 on primary hematopoietic stem/progenitor cells and leukemia progression.

Chiarella E Cell Tissue Res. 2024; 398(3):161-173.

PMID: 39436449 PMC: 11614986. DOI: 10.1007/s00441-024-03926-2.


U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review).

Nian Q, Li Y, Li J, Zhao L, Rodrigues Lima F, Zeng J Oncol Rep. 2023; 51(1).

PMID: 37975232 PMC: 10688450. DOI: 10.3892/or.2023.8664.


Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice.

Fisher D, Laranjeira A, Kong T, Snyder S, Shim K, Fulbright M Exp Hematol. 2023; 128:48-66.

PMID: 37611729 PMC: 11227100. DOI: 10.1016/j.exphem.2023.08.005.


Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.

Pearson S, Blance R, Yan F, Hsieh Y, Geary B, Amaral F PLoS One. 2023; 18(5):e0286412.

PMID: 37253035 PMC: 10228771. DOI: 10.1371/journal.pone.0286412.


References
1.
Mercurio F, Zhu H, Murray B, Shevchenko A, Bennett B, Li J . IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997; 278(5339):860-6. DOI: 10.1126/science.278.5339.860. View

2.
Coornaert B, Carpentier I, Beyaert R . A20: central gatekeeper in inflammation and immunity. J Biol Chem. 2008; 284(13):8217-21. PMC: 2659177. DOI: 10.1074/jbc.R800032200. View

3.
Guzman M, Neering S, Upchurch D, Grimes B, Howard D, Rizzieri D . Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001; 98(8):2301-7. DOI: 10.1182/blood.v98.8.2301. View

4.
Park I, He Y, Lin F, Laerum O, Tian Q, Bumgarner R . Differential gene expression profiling of adult murine hematopoietic stem cells. Blood. 2002; 99(2):488-98. DOI: 10.1182/blood.v99.2.488. View

5.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View